Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
about
Use of a rapid throughput in vivo screen to investigate inhibitors of eukaryotic topoisomerase II enzymesGene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cellsDNA topoisomerase II as a target for cancer chemotherapy.Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancerPotentiation of the growth inhibition activity of 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) by Herceptin in SKBR-3 human breast cancer cellsPredictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.Comparative analysis of xanafide cytotoxicity in breast cancer cell lines.DNA topoisomerase IIalpha and -beta expression in human ovarian cancerIntrinsic resistance to chemotherapy in breast cancer.Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.Topoisomerase IIalpha-dependent induction of a persistent DNA damage response in response to transient etoposide exposure.DNA topoisomerase I and II expression in drug resistant germ cell tumoursAromatic extended bisamidines: synthesis, inhibition of topoisomerases, and anticancer cytotoxicity in vitro.Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas.Role of proliferation in HER2 status predicted response to doxorubicin.Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome.
P2860
Q33692759-2874BB17-226C-4D85-A260-2926AB1FBC2BQ34406515-EB6C9D7F-6C63-40B1-83AD-523F5A9B524AQ34718447-546B8680-B211-4A6B-924C-A91054A071BCQ35773929-D8160F36-046B-4F87-93B2-86FDFDFFBA11Q36244099-DD05FCEC-DE30-4ED9-ACE9-915D8ABC4C62Q36293034-1E163921-3B1F-4D0A-82E0-E47186623BB2Q36431775-B8A38008-F325-4080-85CC-46D5A21219DAQ36608659-D4EB333B-271A-449C-ACE9-962E32A552DEQ36618975-28654929-8CD0-41AA-A80E-6E8181647781Q37813694-10F425DB-2FAA-44F8-A79E-C932B2391591Q39715942-A46DCE14-72F4-4AB4-B251-47F537092351Q41130676-A62B9BC0-9531-4B78-B9A8-75A9A9811A57Q42005856-A1AE326F-48F8-4F1B-AFF0-3E42E315A8DCQ43712294-92E30177-5946-4A81-AD6D-F28176C46020Q43993916-607DACAB-EB92-4A67-9177-7CF90445B8C3Q44415276-B82425C8-BD70-4B93-AE2C-DBCEC9E7B835Q44872965-651A03E5-082A-4CD3-B256-5D148BC002DA
P2860
Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Relationship between expressio ...... s in breast cancer cell lines.
@en
Relationship between expressio ...... s in breast cancer cell lines.
@nl
type
label
Relationship between expressio ...... s in breast cancer cell lines.
@en
Relationship between expressio ...... s in breast cancer cell lines.
@nl
prefLabel
Relationship between expressio ...... s in breast cancer cell lines.
@en
Relationship between expressio ...... s in breast cancer cell lines.
@nl
P2093
P2860
P356
P1476
Relationship between expressio ...... s in breast cancer cell lines.
@en
P2093
A L Harris
C M Addison
I D Hickson
I J Stratford
J Carmichael
S Houlbrook
S L Davies
P2860
P2888
P304
P356
10.1038/BJC.1995.529
P407
P577
1995-12-01T00:00:00Z